Literature DB >> 11488526

Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro.

C Etiévant1, A Kruczynski, J M Barret, A S Tait, M Kavallaris, B T Hill.   

Abstract

PURPOSE: Vinflunine (VFL) is a novel Vinca alkaloid with markedly superior experimental in vivo antitumour activity to its parent molecule, vinorelbine (Navelbine, NVB), against a panel of murine and human tumours. The aim of this study was to establish whether there are differences in the rate and extent of development of resistance, both in vivo and in vitro, to these two newer Vinca alkaloids under identical selection conditions.
METHODS: Using P388 leukaemia cells in vivo, it was evident that VFL induced drug resistance far less readily than NVB, as shown by the number of passages required to select for total resistance. Under in vitro conditions, using A549 human lung carcinoma cells, it was also clearly shown by drug sensitivity determinations that VFL was a less-potent inducer of drug resistance than NVB. Resistance resulting from either in vivo or in vitro selection was associated with a classic multidrug resistance profile. Further characterization of the drug-resistance phenotype of the most highly resistant A549 sublines showed that the level of total beta-tubulin expression appeared to be modified exclusively in the NVB-resistant cells.
CONCLUSION: The clear demonstration that resistance to VFL developed far less readily than resistance to NVB both in vivo and in vitro may have potential clinical implications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488526     DOI: 10.1007/s002800100275

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Authors:  Holger Gerullis; Friedhelm Wawroschek; Claus-Henning Köhne; Thorsten Holger Ecke
Journal:  Ther Adv Urol       Date:  2016-11-21

Review 2.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.

Authors:  Ashish Aggarwal; Anna Kruczynski; Anthony Frankfurter; John J Correia; Sharon Lobert
Journal:  Invest New Drugs       Date:  2007-12-11       Impact factor: 3.850

4.  Vinflunine in the treatment of bladder cancer.

Authors:  Mark Bachner; Maria De Santis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

5.  Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.

Authors:  Cindy Simoens; Filip Lardon; Bea Pauwels; Christel M J De Pooter; Hilde A J Lambrechts; Greet G O Pattyn; Fabienne Breillout; Jan B Vermorken
Journal:  BMC Cancer       Date:  2008-02-29       Impact factor: 4.430

Review 6.  Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.

Authors:  Armand Morel; Denis Talbot
Journal:  Open Access J Urol       Date:  2010-06-29

Review 7.  Cancer wars: natural products strike back.

Authors:  Christine Basmadjian; Qian Zhao; Embarek Bentouhami; Amel Djehal; Canan G Nebigil; Roger A Johnson; Maria Serova; Armand de Gramont; Sandrine Faivre; Eric Raymond; Laurent G Désaubry
Journal:  Front Chem       Date:  2014-05-01       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.